Interestingly, none of the five additional genes of interest (C-Myc, NPM1, FBL, NHP2L1, NOP58) showed association with AML patient outcome, supporting the specificity of NCL as prognostic marker in AML (Table D in S1 File). This evidence concerns the gene FBL and acute myeloid leukemia.